Montefiore Einstein Center for Cancer Care
Welcome,         Profile    Billing    Logout  
 26 Trials 
170 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coordinator, Site
NCT05216250: Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

Active, not recruiting
2
174
Canada, US
BOTOX, Botulinum Toxin Type A, Placebo for BOTOX
AbbVie
Upper Limb Essential Tremor (UL ET)
11/24
06/25
EAISE, NCT04309474 / 2019-003753-29: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Active, not recruiting
2
121
Europe, Canada, Japan, US, RoW
Elezanumab, ABT-555, Placebo
AbbVie
Acute Ischemic Stroke
04/24
12/24
NCT06032546: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Budigalimab, ABBV-181, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
AbbVie
Human Immuno-deficiency Virus (HIV) Disease
04/25
10/26
NCT05570006: Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Recruiting
2
40
Europe, US
ABBV-668
AbbVie
Ulcerative Colitis
05/26
05/26
ELASCI, NCT04295538 / 2019-003752-36: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Active, not recruiting
2
60
Europe, Canada, Japan, US, RoW
Elezanumab, ABT-555, Placebo
AbbVie
Spinal Cord Injury (SCI)
05/25
02/26
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting
2
146
Japan, US, RoW
TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel
Toray Industries, Inc
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
LUMINOSITY, NCT03539536 / 2018-001772-38: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Active, not recruiting
2
270
Europe, Canada, Japan, US, RoW
Telisotuzumab vedotin, ABBV-399
AbbVie
Non-small Cell Lung Cancer
10/25
10/25
M24-311, NCT06107413: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Recruiting
2
206
Japan, US, RoW
ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan
AbbVie
Unresectable Metastatic Colorectal Cancer
10/26
10/26
NCT05513703: A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
2
9
Europe, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399
AbbVie
Non Small Cell Lung Cancer
03/25
03/26
LIVIGNO-1, NCT05822752: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Recruiting
2
120
Europe, Japan, US, RoW
Budigalimab, ABBV-181, Livmoniplimab, ABBV-151, Lenvatinib, Sorafenib
AbbVie
Hepatocellular Carcinoma
12/26
02/27
NCT02899052 / 2019-004340-30: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Checkmark Data in MM at ASCO 2018
May 2018 - May 2018: Data in MM at ASCO 2018
Active, not recruiting
2
120
Europe, US, RoW
Carfilzomib, Kyprolis, Venetoclax, Venclexta, ABT-199, Dexamethasone
AbbVie, Genentech, Inc; Onyx Therapeutics, Inc.
Multiple Myeloma
06/27
06/27
EPCORE NHL-6, NCT05451810: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Recruiting
2
184
US
Epcoritamab, ABBV-GMAB-3013
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
08/27
05/29
NCT05291234: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Recruiting
2
195
US
ABBV-916, Placebo
AbbVie
Alzheimer's Disease (AD)
03/31
03/31
NCT04403763: Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Terminated
1/2
80
US
AGN-241622, Vehicle
AbbVie
Presbyopia
12/22
12/22
NCT04807972 / 2020-005767-31: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Completed
1/2
40
Europe, US, RoW
ABBV-927, Budiglimab, ABBV-181, modified FOLFIRINOX, mFFX
AbbVie
Pancreatic Cancer
03/24
03/24
NCT06158854: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion

Recruiting
1/2
76
Japan, US, RoW
ABBV-383, TNB-383B
AbbVie
Immunoglobulin Light Chain (AL) Amyloidosis
12/25
02/28
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/24
03/27
NCT04499248: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Recruiting
1/2
96
Japan, US
AGN-193408 SR, Lumigan, Active Comparator, Sham Administration, Lumigan Vehicle, Vehicle
AbbVie
Open-angle Glaucoma, Ocular Hypertension
08/27
08/27
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
640
RoW
YL201 for Injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor
10/26
10/27
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Recruiting
1/2
65
Europe, Canada, US, RoW
Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group
Acute Myeloid Leukemia
05/27
05/27
NCT05895266: A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers

Completed
1
24
US
ABBV-903, Midazolam
AbbVie
Healthy Volunteer
11/23
11/23
NCT06148181: A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

Active, not recruiting
1
99
US
ABBV-141, Placebo for ABBV-141
AbbVie
Healthy Volunteers
01/25
01/25
NCT06158958: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Recruiting
1
192
Japan, US, RoW
ABBV-303, Budigalimab, ABBV-181
AbbVie
Solid Tumors
01/28
01/28
NCT04189614: An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Active, not recruiting
1
65
Europe, Japan, US, RoW
Cofetuzumab Pelidotin, ABBV-647
AbbVie, Pfizer
Cancer, Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
M14-237, NCT02099058: A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Active, not recruiting
1
237
Europe, Japan, US, RoW
Osimertinib, Nivolumab, Telisotuzumab vedotin, ABBV-399, Erlotinib
AbbVie
Advanced Solid Tumors Cancer
11/24
11/24
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Recruiting
1
155
US
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
NCT05892757: Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Completed
1
24
US
Atogepant, QULIPTA, Ubrogepant, UBRELVY
AbbVie
Healthy Volunteers
02/24
02/24
NCT05434234: A Study of YL201 in Patients With Advanced Solid Tumors

Recruiting
1
196
US, RoW
YL201
MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor
07/24
07/25
NCT04454658: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Active, not recruiting
1
21
Europe, Japan, US, RoW
ABBV-744, Navitoclax, ABT-263, Ruxolitinib
AbbVie
Myelofibrosis (MF)
11/24
11/24
NCT03639194: A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Completed
1
132
Japan, US, RoW
ABBV-011, SC-011, Budigalimab, ABBV-181
AbbVie
Small Cell Lung Cancer
01/24
01/24
NCT04041050: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Active, not recruiting
1
85
Europe, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Celecoxib, Celebrex
AbbVie
Myeloproliferative Neoplasm
01/25
01/25
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Recruiting
1
180
Japan, US
DS-6000a, R-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Ovarian Tumor
11/24
11/24
YL202-INT-101-01, NCT05653752: A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active, not recruiting
1
80
US, RoW
YL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Non Small Cell Lung Cancer, Breast Cancer
12/24
12/25
NCT03821935: Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
362
Europe, Canada, Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181
AbbVie
Advanced Solid Tumors Cancer
06/27
06/27
NCT05005403: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Recruiting
1
268
Japan, US, RoW
ABBV-514, Budigalimab, ABBV-181
AbbVie
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
05/26
05/26
NCT05650632: A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
120
Europe, Canada, US, RoW
ABBV-383
TeneoOne Inc.
Multiple Myeloma
07/26
07/26
NCT05956509: Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

Terminated
1
1
US
ABBV-950, Botulinum toxin type A, BOTOX, OnabotulinumtoxinA, Placebo for ABBV-950
AbbVie
Upper Limb Spasticity
06/24
06/24
NCT03725007 / 2018-000715-25: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

Active, not recruiting
1
122
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494
AbbVie, AbbVie Inc.
Juvenile Idiopathic Arthritis (JIA)
05/27
05/27
NCT05259839: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1
270
Europe, Japan, US, RoW
ABBV-383, Dexamethasone, Lenalidomide, Pomalidomide, Nirogacestat, Daratumumab
TeneoOne Inc.
Relapsed/Refractory Multiple Myeloma
11/28
07/31
METER, NCT05444972: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Completed
N/A
998
Europe, Canada, US, RoW
AbbVie
Myelofibrosis
11/23
11/23
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Completed
N/A
450
RoW
Daiichi Sankyo Co., Ltd.
Gastric Cancer
11/23
11/23
NCT04496518: Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

Recruiting
N/A
2200
Europe, US
Intrinsic Antitachycardia Pacing (iATP) Therapy
Medtronic
Ventricular Tachycardia
01/25
01/27
NCT04489225: Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

Recruiting
N/A
2200
Europe, US
Observational
Medtronic
Heart Failure
01/25
01/27
AD-VISE, NCT05081557: A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

Recruiting
N/A
975
Europe, Canada, RoW
AbbVie
Atopic Dermatitis
10/25
10/26
LIVEN, NCT05424562: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

Recruiting
N/A
270
Canada
AbbVie
Acute Myeloid Leukemia
06/26
06/26
ASQ, NCT04024943: Personalized Therapy Study - Attain Stability Quad Post-Approval Study

Active, not recruiting
N/A
1008
Europe, US
Quadripolar LV Lead, Medtronic CRT-P, Medtronic CRT-D
Medtronic
Heart Failure
01/27
04/27
PROFUNDUS, NCT05494606: An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

Recruiting
N/A
1000
Europe, Canada, RoW
AbbVie
Ulcerative Colitis
03/28
03/28
APPRISE, NCT05841537: An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

Recruiting
N/A
1000
Europe, Canada, Japan, RoW
AbbVie
Crohn's Disease
01/28
01/28
ROSSINI, NCT06107426: Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Recruiting
N/A
450
Europe, RoW
AbbVie
Parkinson's Disease (PD)
05/29
05/29
UPlift, NCT05930275: Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

Recruiting
N/A
1200
Europe, Canada, Japan, RoW
AbbVie
Crohn's Disease
09/28
09/28
Ghalib, Mohammad
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
Mamczur-Madry, Magdalena
PACES, NCT04045665: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting
3
3200
Europe, Canada, US
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center
Atrial Fibrillation, Stroke, Bleeding
06/25
06/25
NCT03639025: OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Recruiting
N/A
555
US
OCS Lung System
TransMedics
Lung Transplantation
08/26
08/30
Cole, Yvette
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
TPST-1495-001, NCT04344795: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Active, not recruiting
1
175
US
TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab, Keytruda
Tempest Therapeutics
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
09/24
10/24
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Active, not recruiting
1
198
Europe, US
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
06/25
06/25
TH1902-CTR-0001, NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Recruiting
1
70
Canada, US
TH1902, TH1902 peptide-drug conjugate
Theratechnologies, PPD, Altasciences Company Inc., Windtree Therapeutics, Syneos Health, Innovaderm Research Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
12/24
12/24
Suarez, Melissa
NCT04815083: Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

Recruiting
3
370
US
Aminolevulinic Acid Hydrochloride, PD G 506 A, Eagle V1.2 Imaging System, Placebo
SBI ALApharma Canada, Inc.
Breast Neoplasm Female, Breast Cancer
05/25
06/26
NCT05330598: Evaluation of the Safety and Clinical Performance of the Connected Catheter Study

Terminated
N/A
26
US
Connected Catheter
Spinal Singularity
Urinary Retention, Chronic
02/24
02/24
ALAMO, NCT05050955: AlloSure Lung Assessment and Metagenomics Outcomes Study

Recruiting
N/A
500
US
CareDx
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
12/28
12/28
McLellan, Beth
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Active, not recruiting
2
170
US, RoW
OQL011, Vehicle Ointment
OnQuality Pharmaceuticals (USA) LLC
Hand-Foot Skin Reaction (HFSR)
02/24
06/24
CLEER, NCT05639933: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Recruiting
2
152
US
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Hoth Therapeutics, Inc., Worldwide Clinical Trials
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
12/24
01/25
NCT05213936: Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color

Recruiting
N/A
30
US
Scalp cooling with hairstyle, Scalp cooling with conditioner and water emulsion
Montefiore Medical Center, Paxman
Alopecia
01/25
01/25
Victor, Joel
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
SY-1425-202, NCT04905407: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals
Acute Myeloid Leukemia
04/28
04/28
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Calendar Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/24
12/24
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
NCT05225584: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Recruiting
1
120
US
KT-333
Kymera Therapeutics, Inc.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
02/25
03/25
ANTLER, NCT04637763: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Recruiting
1
72
US, RoW
CB-010, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
08/25
09/25
Deutsch, Alana
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Active, not recruiting
2
170
US, RoW
OQL011, Vehicle Ointment
OnQuality Pharmaceuticals (USA) LLC
Hand-Foot Skin Reaction (HFSR)
02/24
06/24
 

Download Options